A phase 1 pharmacokinetic and pharmacodynamic trial comparing extended release (XR) of Ralinepag to the immediate release (IR) formulation of Ralinepag in healthy volunteers
Latest Information Update: 07 May 2019
Price :
$35 *
At a glance
- Drugs Ralinepag (Primary)
- Indications Pulmonary arterial hypertension
- Focus Pharmacodynamics; Pharmacokinetics
- 06 Apr 2019 Results presented at the 39th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation
- 29 Jun 2017 Status changed from recruiting to completed, according to an Arena Pharmaceuticals media release.
- 29 Jun 2017 Results published in an Arena Pharmaceuticals media release.